![Echocardiographic parameters associated with in‐hospital adverse outcomes in patients with Takotsubo syndrome - Farina - 2021 - Echocardiography - Wiley Online Library Echocardiographic parameters associated with in‐hospital adverse outcomes in patients with Takotsubo syndrome - Farina - 2021 - Echocardiography - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/fcb4ea0e-1a8e-449b-95d7-6007462c7fbe/echo.v38.6.cover.jpg?trick=1670814793767)
Echocardiographic parameters associated with in‐hospital adverse outcomes in patients with Takotsubo syndrome - Farina - 2021 - Echocardiography - Wiley Online Library
Turki Alelyani, Stevens Institute of Technology, Arup Kumar Ghosh, Jacksonville State University Larry Moralez, University of Ce
![Discovery of 3-Cyano-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist | Journal of ... Discovery of 3-Cyano-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist | Journal of ...](https://pubs.acs.org/cms/10.1021/acs.jmedchem.8b00392/asset/images/large/jm-2018-003925_0009.jpeg)
Discovery of 3-Cyano-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist | Journal of ...
![Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer | Journal for ImmunoTherapy of Cancer Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/8/2/e000698/F2.large.jpg)
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer | Journal for ImmunoTherapy of Cancer
Jeremy Irons | A message from Jeremy Irons, Patron of The Greater Chernobyl Cause. | By The Greater Chernobyl Cause | Facebook
![Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets | Journal of Medicinal Chemistry Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.1c01694/asset/images/medium/jm1c01694_0017.gif)
Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets | Journal of Medicinal Chemistry
![INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology | ACS Medicinal Chemistry Letters INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology | ACS Medicinal Chemistry Letters](https://pubs.acs.org/cms/10.1021/acsmedchemlett.6b00391/asset/images/large/ml-2016-00391h_0001.jpeg)
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology | ACS Medicinal Chemistry Letters
![Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities | Oncogene Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities | Oncogene](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41388-020-1284-6/MediaObjects/41388_2020_1284_Fig1_HTML.png)
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities | Oncogene
Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets | Journal of Medicinal Chemistry
![Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy - European Journal of Cancer Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy - European Journal of Cancer](https://www.ejcancer.com/cms/asset/c045b401-591b-4d54-870a-38b121f566e5/gr3.jpg)
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy - European Journal of Cancer
![Factors That Predict Biological Aggressiveness in Estrogen Receptor–Positive / Human Epidermal Growth Factor Receptor 2–Negative / Lymph Node–Negative Breast Cancer | Ochsner Journal Factors That Predict Biological Aggressiveness in Estrogen Receptor–Positive / Human Epidermal Growth Factor Receptor 2–Negative / Lymph Node–Negative Breast Cancer | Ochsner Journal](https://www.ochsnerjournal.org/sites/default/files/highwire/ochjnl/20/4.cover-source.jpg)
Factors That Predict Biological Aggressiveness in Estrogen Receptor–Positive / Human Epidermal Growth Factor Receptor 2–Negative / Lymph Node–Negative Breast Cancer | Ochsner Journal
![Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study - Ralph HB Benedict, Stanley Cohan, Sharon G Lynch, Katherine Riester, Ping Wang, Wanda Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study - Ralph HB Benedict, Stanley Cohan, Sharon G Lynch, Katherine Riester, Ping Wang, Wanda](https://journals.sagepub.com/cms/10.1177/1352458517707345/asset/images/large/10.1177_1352458517707345-fig1.jpeg)
Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study - Ralph HB Benedict, Stanley Cohan, Sharon G Lynch, Katherine Riester, Ping Wang, Wanda
![Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial - The Lancet Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/46a11b47-b14c-4e31-8358-9335eb4bbe68/gr1_lrg.gif)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial - The Lancet
![Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives | Journal of Medicinal Chemistry Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.0c01093/asset/images/large/jm0c01093_0009.jpeg)